Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I study.
Röllig C, Schliemann C, Ruhnke L, Fransecky L, Heydrich BN, Hanoun M, Noppeney R, Schäfer-Eckart K, Wendelin K, Mikesch JH, Middeke JM, Reimann M, Fiebig F, Zukunft S, Wermke M, Serve H, Platzbecker U, Müller-Tidow C, Baldus CD, Bornhäuser M. Röllig C, et al. Among authors: wermke m. Br J Haematol. 2024 Apr 9. doi: 10.1111/bjh.19436. Online ahead of print. Br J Haematol. 2024. PMID: 38593353
A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy.
Wass M, Göllner S, Besenbeck B, Schlenk RF, Mundmann P, Göthert JR, Noppeney R, Schliemann C, Mikesch JH, Lenz G, Dugas M, Wermke M, Röllig C, Bornhäuser M, Serve H, Platzbecker U, Foerster KI, Burhenne J, Haefeli WE, Müller LP, Binder M, Pabst C, Müller-Tidow C; Study Alliance Leukemia (SAL). Wass M, et al. Among authors: wermke m. Leukemia. 2021 Mar;35(3):701-711. doi: 10.1038/s41375-020-0892-z. Epub 2020 Jun 19. Leukemia. 2021. PMID: 32561840 Free PMC article. Clinical Trial.
Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse.
Berdel AF, Ruhnke L, Angenendt L, Wermke M, Röllig C, Mikesch JH, Scheller A, Hemmerle T, Matasci M, Wethmar K, Kessler T, Gerwing M, Hescheler D, Schäfers M, Hartmann W, Altvater B, Rossig C, Bornhäuser M, Lenz G, Stelljes M, Rueter B, Neri D, Berdel WE, Schliemann C. Berdel AF, et al. Among authors: wermke m. Blood Adv. 2022 Jun 28;6(12):3684-3696. doi: 10.1182/bloodadvances.2021006909. Blood Adv. 2022. PMID: 35468621 Free PMC article. Clinical Trial.
Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial.
Röllig C, Bornhäuser M, Kramer M, Thiede C, Ho AD, Krämer A, Schäfer-Eckart K, Wandt H, Hänel M, Einsele H, Aulitzky WE, Schmitz N, Berdel WE, Stelljes M, Müller-Tidow C, Krug U, Platzbecker U, Wermke M, Baldus CD, Krause SW, Stölzel F, von Bonin M, Schaich M, Serve H, Schetelig J, Ehninger G. Röllig C, et al. Among authors: wermke m. J Clin Oncol. 2015 Feb 10;33(5):403-10. doi: 10.1200/JCO.2013.54.4973. Epub 2014 Dec 29. J Clin Oncol. 2015. PMID: 25547501
Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of Relapse.
Sockel K, Stölzel F, Hönl F, Baldauf H, Röllig C, Wermke M, von Bonin M, Teipel R, Link-Rachner C, Brandt K, Kroschinsky F, Hänel M, Morgner A, Klesse C, Ehninger G, Platzbecker U, Bornhäuser M, Schetelig J, Middeke JM. Sockel K, et al. Among authors: wermke m. Cancer Manag Res. 2022 Feb 15;14:547-559. doi: 10.2147/CMAR.S339846. eCollection 2022. Cancer Manag Res. 2022. PMID: 35210852 Free PMC article.
188Re anti-CD66 radioimmunotherapy combined with reduced-intensity conditioning and in-vivo T cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantation.
Lauter A, Strumpf A, Platzbecker U, Schetelig J, Wermke M, Radke J, Kiani A, Wunderlich G, Thiede C, Ehninger G, Kotzerke J, Bornhäuser M. Lauter A, et al. Among authors: wermke m. Br J Haematol. 2010 Mar;148(6):910-7. doi: 10.1111/j.1365-2141.2009.08025.x. Epub 2009 Dec 7. Br J Haematol. 2010. PMID: 19995390 Free article. Clinical Trial.
Mammalian-target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D-MDS).
Wermke M, Schuster C, Nolte F, Al-Ali HK, Kiewe P, Schönefeldt C, Jakob C, von Bonin M, Hentschel L, Klut IM, Ehninger G, Bornhäuser M, Baretton G, Germing U, Herbst R, Haase D, Hofmann WK, Platzbecker U. Wermke M, et al. Br J Haematol. 2016 Dec;175(5):917-924. doi: 10.1111/bjh.14345. Epub 2016 Oct 7. Br J Haematol. 2016. PMID: 27714772 Free article. Clinical Trial.
Reconstitution of 6-sulfo LacNAc dendritic cells after allogeneic stem-cell transplantation.
Mager K, Wehner R, Bahr F, Oelschlägel U, Platzbecker U, Wermke M, Shayegi N, Middeke JM, Radke J, Röllig C, Schetelig J, Thiede C, Ehninger G, Schmitz M, Bornhäuser M, Tuve S. Mager K, et al. Among authors: wermke m. Transplantation. 2012 Jun 27;93(12):1270-5. doi: 10.1097/TP.0b013e31824fd8b4. Transplantation. 2012. PMID: 22643330
Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial.
Wermke M, Eckoldt J, Götze KS, Klein SA, Bug G, de Wreede LC, Kramer M, Stölzel F, von Bonin M, Schetelig J, Laniado M, Plodeck V, Hofmann WK, Ehninger G, Bornhäuser M, Wolf D, Theurl I, Platzbecker U. Wermke M, et al. Lancet Haematol. 2018 May;5(5):e201-e210. doi: 10.1016/S2352-3026(18)30036-X. Epub 2018 Apr 5. Lancet Haematol. 2018. PMID: 29628397
98 results